康众医疗(688607) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥81,136,819.16, an increase of 21.80% compared to the same period last year[4] - The net profit attributable to shareholders was ¥1,087,381.54, a decrease of 79.36% year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥958,248.36, with a significant decrease compared to the previous year[10] - Total operating revenue for the first three quarters of 2025 reached ¥226,019,950.40, an increase of 15.6% compared to ¥195,501,808.26 in the same period of 2024[20] - The net profit for the first three quarters of 2025 was ¥110,187.00, a significant decrease from ¥12,591,909.69 in 2024[21] - The company reported a comprehensive income total of ¥471,124.66 for the first three quarters of 2025, compared to ¥9,291,941.91 in 2024[22] Expenses and Costs - Research and development expenses totaled ¥8,378,646.61, accounting for 10.33% of operating revenue, a decrease of 4.01 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were ¥23,852,161.81, down from ¥30,522,635.51 in 2024, a decrease of 21.9%[21] - Total operating costs for the first three quarters of 2025 were ¥220,453,690.46, up from ¥187,959,296.34 in 2024, reflecting a growth of 17.3%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥988,475,321.06, reflecting a 2.23% increase from the end of the previous year[5] - The total liabilities increased to ¥130,202,196.49 in 2025 from ¥104,440,158.13 in 2024, marking a rise of 24.7%[18] - The total assets amounted to ¥988,475,321.06 in 2025, compared to ¥966,947,228.28 in 2024, indicating a growth of 2.7%[18] - The total non-current liabilities decreased to ¥10,397,316.59 in 2025 from ¥15,539,425.43 in 2024, a decline of 33.2%[18] - The company's total equity as of 2025 was ¥858,273,124.57, slightly down from ¥862,507,070.15 in 2024[18] Cash Flow - The cash flow from operating activities for the year-to-date was -¥73,601,209.17, a decrease of ¥98,715,449.18 compared to the same period last year[10] - The cash flow from operating activities for the first three quarters of 2025 was ¥235,619,980.16, an increase from ¥219,284,143.39 in 2024[24] - Net cash flow from operating activities was -73,601,209.17, a decrease from 25,114,240.01 in the previous period[25] - Total cash inflow from investment activities was 1,318,651,411.44, down from 1,830,617,049.82 year-over-year[25] - Cash outflow from investment activities totaled 1,358,210,229.36, compared to 1,811,350,905.45 in the prior period[25] - Net cash flow from financing activities was 23,858,281.86, a significant improvement from -19,417,673.77 previously[27] - The ending cash and cash equivalents balance was 131,884,293.73, down from 263,454,691.58 at the end of the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,861[12] - Liu Jianqiang holds 12,810,000 shares, representing 14.54% of total shares[12] - The top three shareholders collectively hold 31.58% of the total shares[12] - The company has no preferred shareholders with restored voting rights[12] - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending[14] Inventory and Investments - The company has committed to maintaining a safe inventory level in response to macroeconomic changes, including tax adjustments[10] - The company reported current assets totaling 584,026,459.76 RMB as of September 30, 2025, compared to 607,838,779.06 RMB at the end of 2024[16] - The cash and cash equivalents decreased from 271,907,862.48 RMB to 131,884,293.73 RMB[15] - The company's long-term equity investments increased from 128,400,095.93 RMB to 153,653,801.55 RMB[16] - The inventory value rose significantly from 85,966,534.06 RMB to 156,076,465.33 RMB[16] Non-Recurring Gains and Losses - The total non-recurring gains and losses for the period amounted to ¥2,045,629.90, with a year-to-date total of ¥4,696,231.54[8] - The company experienced a significant decline in net profit due to reduced investment income from financial assets and increased provisions for bad debts[10] - Cash received from investment income was 4,393,788.88, down from 7,939,949.82 in the previous period[25] - Cash inflow from other investment activities was 1,314,124,500.00, compared to 1,822,677,100.00 in the previous year[25] - Cash paid for the purchase of fixed assets and intangible assets was 28,442,129.36, a decrease from 70,038,739.93 year-over-year[25] Related Party Transactions - There are no significant related party transactions disclosed in the report[14]